Nohla Therapeutics is the world leader in development of ex vivo expanded universal donor cellular therapies, available on demand for treatment of life threatening diseases
About Nohla Therapeutics
Our scientific platform
Nohla Therapeutics has pioneered a technique to rapidly grow hematopoietic stem and progenitor cells by up to 500-fold using the Notch ligand Delta1—a protein which activates endogenous Notch signaling in the stem/progenitor cells, which inhibits their differentiation.
See the progress of our pipeline
Life changing treatment
Nohla Therapeutics’ universal donor product has been used to treat over 100 patients, bringing hope to patients who previously had limited options.
Our extraordinary team
Nohla has recruited a team of the greatest hearts and minds in cancer research